[
  {
    "ts": null,
    "headline": "Quanterix Announces Board and Leadership Changes to Support Next Stage of Growth",
    "summary": "BILLERICA, Mass., November 20, 2025--Quanterix Corporation (\"Quanterix\" or the \"Company\") (NASDAQ: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced a series of leadership and governance enhancements designed to support the Company’s next phase of growth. These changes include the appointment of two highly accomplished life sciences executives, Garret Hampton, Ph.D., and Alan Sachs, M.D., Ph.D., to the Company’s Board",
    "url": "https://finnhub.io/api/news?id=bfa69fce30c36479bb25c1fce7bf8181dd750a41d8d506613011eb2e345bf41d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763673300,
      "headline": "Quanterix Announces Board and Leadership Changes to Support Next Stage of Growth",
      "id": 137566601,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "TMO",
      "source": "Yahoo",
      "summary": "BILLERICA, Mass., November 20, 2025--Quanterix Corporation (\"Quanterix\" or the \"Company\") (NASDAQ: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced a series of leadership and governance enhancements designed to support the Company’s next phase of growth. These changes include the appointment of two highly accomplished life sciences executives, Garret Hampton, Ph.D., and Alan Sachs, M.D., Ph.D., to the Company’s Board",
      "url": "https://finnhub.io/api/news?id=bfa69fce30c36479bb25c1fce7bf8181dd750a41d8d506613011eb2e345bf41d"
    }
  },
  {
    "ts": null,
    "headline": "Thermo Fisher Scientific’s Oncomine Dx Target Test Receives FDA Approval as a Companion Diagnostic to Identify Patients Eligible for Newest Targeted Therapy for Non-Small Cell Lung Cancer",
    "summary": "CARLSBAD, Calif., November 20, 2025--Thermo Fisher Scientific, the world leader in serving science, has received approval from the U.S. Food and Drug Administration (FDA) for its Ion Torrent™ Oncomine™ Dx Target Test as a companion diagnostic (CDx) to identify patients who may be eligible for treatment with HYRNUO™ (sevabertinib), a new HER2-directed therapy developed and commercialized by Bayer. The test enables clinicians and pathologists to identify non-small cell lung cancer (NSCLC) tumors w",
    "url": "https://finnhub.io/api/news?id=8b38f323d8407cc751beec7aeb15f15baf4908b5f99f004e7c4e3f425593efd8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763644500,
      "headline": "Thermo Fisher Scientific’s Oncomine Dx Target Test Receives FDA Approval as a Companion Diagnostic to Identify Patients Eligible for Newest Targeted Therapy for Non-Small Cell Lung Cancer",
      "id": 137556488,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "TMO",
      "source": "Yahoo",
      "summary": "CARLSBAD, Calif., November 20, 2025--Thermo Fisher Scientific, the world leader in serving science, has received approval from the U.S. Food and Drug Administration (FDA) for its Ion Torrent™ Oncomine™ Dx Target Test as a companion diagnostic (CDx) to identify patients who may be eligible for treatment with HYRNUO™ (sevabertinib), a new HER2-directed therapy developed and commercialized by Bayer. The test enables clinicians and pathologists to identify non-small cell lung cancer (NSCLC) tumors w",
      "url": "https://finnhub.io/api/news?id=8b38f323d8407cc751beec7aeb15f15baf4908b5f99f004e7c4e3f425593efd8"
    }
  },
  {
    "ts": null,
    "headline": "TMO Stock May Rise Post New PCR Test in Collab With Coca-Cola Partner",
    "summary": "Thermo Fisher's new all-in-one SureTect qPCR assay promises faster, broader beverage spoilage detection and sharper quality control.",
    "url": "https://finnhub.io/api/news?id=444d1e91ac11605d8877ceedc4cecb8759f70b2a56bef2baf817837b45b40c5b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763642940,
      "headline": "TMO Stock May Rise Post New PCR Test in Collab With Coca-Cola Partner",
      "id": 137556444,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "TMO",
      "source": "Yahoo",
      "summary": "Thermo Fisher's new all-in-one SureTect qPCR assay promises faster, broader beverage spoilage detection and sharper quality control.",
      "url": "https://finnhub.io/api/news?id=444d1e91ac11605d8877ceedc4cecb8759f70b2a56bef2baf817837b45b40c5b"
    }
  },
  {
    "ts": null,
    "headline": "OutSystems Agent Workbench Accelerates Enterprise Agentic AI Adoption",
    "summary": "OutSystems, the leading AI-powered low-code development platform, today announced strong early momentum for Agent Workbench, its enterprise-grade platform for building and orchestrating intelligent AI agents across data sets, workflows, or systems. Following its general availability launch on September 30, enterprises across industries are already using Agent Workbench to accelerate agentic transformation, moving from pilots to production and orchestrating multi-agent workflows with built-in hum",
    "url": "https://finnhub.io/api/news?id=98f7119e16d2cf46857cee30ebd9bd3ab4ab2834fef4923d8dfe43a9a35a2978",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763614800,
      "headline": "OutSystems Agent Workbench Accelerates Enterprise Agentic AI Adoption",
      "id": 137554021,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "TMO",
      "source": "Yahoo",
      "summary": "OutSystems, the leading AI-powered low-code development platform, today announced strong early momentum for Agent Workbench, its enterprise-grade platform for building and orchestrating intelligent AI agents across data sets, workflows, or systems. Following its general availability launch on September 30, enterprises across industries are already using Agent Workbench to accelerate agentic transformation, moving from pilots to production and orchestrating multi-agent workflows with built-in hum",
      "url": "https://finnhub.io/api/news?id=98f7119e16d2cf46857cee30ebd9bd3ab4ab2834fef4923d8dfe43a9a35a2978"
    }
  },
  {
    "ts": null,
    "headline": "The Bull Case For Thermo Fisher Scientific (TMO) Could Change Following EXENT System Clearance and New Philly Center Opening – Learn Why",
    "summary": "Thermo Fisher Scientific recently received U.S. 510(k) clearance for its EXENT System, an automated analyser aimed at improving the diagnosis of multiple myeloma, and announced the grand opening of its East Coast Advanced Therapies Collaboration Center in Philadelphia to support cell and gene therapy innovation. These milestones expand Thermo Fisher's expertise in diagnostics and advanced therapies, providing researchers and clinicians with new tools and infrastructure to accelerate...",
    "url": "https://finnhub.io/api/news?id=59b5be523c482e0970d9cf69a4194907e241c98566f4e19f81ff5b55847131fd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763608910,
      "headline": "The Bull Case For Thermo Fisher Scientific (TMO) Could Change Following EXENT System Clearance and New Philly Center Opening – Learn Why",
      "id": 137554023,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "TMO",
      "source": "Yahoo",
      "summary": "Thermo Fisher Scientific recently received U.S. 510(k) clearance for its EXENT System, an automated analyser aimed at improving the diagnosis of multiple myeloma, and announced the grand opening of its East Coast Advanced Therapies Collaboration Center in Philadelphia to support cell and gene therapy innovation. These milestones expand Thermo Fisher's expertise in diagnostics and advanced therapies, providing researchers and clinicians with new tools and infrastructure to accelerate...",
      "url": "https://finnhub.io/api/news?id=59b5be523c482e0970d9cf69a4194907e241c98566f4e19f81ff5b55847131fd"
    }
  }
]